Solid Biosciences Inc. (SLDB) News
Filter SLDB News Items
SLDB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SLDB News Highlights
- SLDB's 30 day story count now stands at 2.
- Over the past 5 days, the trend for SLDB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about SLDB are CELL and GENE.
Latest SLDB News From Around the Web
Below are the latest news stories about SOLID BIOSCIENCES INC that investors may wish to consider to help them evaluate SLDB as an investment opportunity.
Solid Biosciences to Participate at Upcoming Investor ConferencesCHARLESTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the following three upcoming investor conferences: Jefferies Cell & Genetic Medicines Summit - New York, NYPresenting on Wednesday, September 27, 2023, at 10:00 AM ET.Cantor Global Healthcare Conference - New York, NYPresen |
Solid Biosciences to Participate in Citi’s 18th Annual BioPharma ConferenceCHARLESTOWN, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Citi 18th Annual BioPharma Conference on Thursday, September 7, 2023, at 9:40 AM ET. A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here |
Solid Biosciences Provides Second Quarter Business Update and Financial Results– On track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy (Duchenne) – – Executed licensing agreement for development and commercialization of gene therapies in certain fatal cardiac disorders – – Company ends second quarter with approximately $160.2 million in cash and investments; Anticipated cash runway into 2025 – CHARLESTOWN, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences com |
Solid Biosciences to Participate at the Jefferies Healthcare ConferenceCHARLESTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 3:00 PM ET. A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by c |
Solid Biosciences to Participate at the Barclays Gene Editing & Therapy SummitCHARLESTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in a fireside chat at the Barclays Gene Editing & Therapy Summit on Wednesday, May 24, 2023 at 11:30 AM ET. A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website |
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting— Oral presentation highlighting data from multiple animal models demonstrated administration of AVB-202 resulted in frataxin (FXN) expression in cardiac and central nervous system (CNS) tissues with a favorable safety profile and may improve cardiac function and extend survival — — Five additional abstracts relating to the company’s next-generation capsid activities, adeno-associated vector manufacturing methods and quality assurance assays to be presented as posters — CHARLESTOWN, Mass., May 1 |
Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue EstimatesSolid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15.85% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Solid Biosciences Provides First Quarter Business Update and Financial Results– Company remains on track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy (Duchenne) – – Company ends first quarter with approximately $185.5 million in cash and investments; Anticipated cash runway into 2025 – CHARLESTOWN, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today reported financial results for |
Solid Biosciences to Present at JMP Securities Life Sciences ConferenceCHARLESTOWN, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 1:00 PM ET. A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A web |
Solid Biosciences to Participate in Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing SummitCHARLESTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Solid management will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 24, 2023 at 2:00 PM ET. A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company websi |